Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Increased platelet activation in sleep apnea subjects with intermittent hypoxemia.

Krieger AC, Anand R, Hernandez-Rosa E, Maidman A, Milrad S, DeGrazia MQ, Choi AJ, Oromendia C, Marcus AJ, Drosopoulos JHF.

Sleep Breath. 2020 Feb 8. doi: 10.1007/s11325-020-02021-4. [Epub ahead of print]

PMID:
32036486
2.

Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk.

Moeckel D, Jeong SS, Sun X, Broekman MJ, Nguyen A, Drosopoulos JH, Marcus AJ, Robson SC, Chen R, Abendschein D.

Sci Transl Med. 2014 Aug 6;6(248):248ra105. doi: 10.1126/scitranslmed.3009246.

3.

CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia.

Pulte D, Furman RR, Broekman MJ, Drosopoulos JH, Ballard HS, Olson KE, Kizer JR, Marcus AJ.

Clin Lymphoma Myeloma Leuk. 2011 Aug;11(4):367-72. doi: 10.1016/j.clml.2011.06.005.

4.

Human solCD39 inhibits injury-induced development of neointimal hyperplasia.

Drosopoulos JH, Kraemer R, Shen H, Upmacis RK, Marcus AJ, Musi E.

Thromb Haemost. 2010 Feb;103(2):426-34. doi: 10.1160/TH09-05-0305. Epub 2009 Dec 18.

5.

CD39/NTPDase-1 activity and expression in normal leukocytes.

Pulte ED, Broekman MJ, Olson KE, Drosopoulos JH, Kizer JR, Islam N, Marcus AJ.

Thromb Res. 2007;121(3):309-17. Epub 2007 Jun 7.

6.

Constraints imposed by transmembrane domains affect enzymatic activity of membrane-associated human CD39/NTPDase1 mutants.

Musi E, Islam N, Drosopoulos JH.

Arch Biochem Biophys. 2007 May 1;461(1):30-9. Epub 2007 Mar 2.

PMID:
17374358
7.

The ratio of ADP- to ATP-ectonucleotidase activity is reduced in patients with coronary artery disease.

El-Omar MM, Islam N, Broekman MJ, Drosopoulos JH, Roa DC, Lorin JD, Sedlis SP, Olson KE, Pulte ED, Marcus AJ.

Thromb Res. 2005;116(3):199-206. Epub 2004 Dec 21.

PMID:
15935828
8.

Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection.

Marcus AJ, Broekman MJ, Drosopoulos JH, Olson KE, Islam N, Pinsky DJ, Levi R.

Semin Thromb Hemost. 2005 Apr;31(2):234-46. Review.

PMID:
15852226
9.

Heterologous cell-cell interactions: thromboregulation, cerebroprotection and cardioprotection by CD39 (NTPDase-1).

Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Pinsky DJ, Sesti C, Levi R.

J Thromb Haemost. 2003 Dec;1(12):2497-509. Review. Erratum in: J Thromb Haemost. 2004 Apr;2(4):682.

10.

Metabolic control of excessive extracellular nucleotide accumulation by CD39/ecto-nucleotidase-1: implications for ischemic vascular diseases.

Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Pinsky DJ, Sesti C, Levi R.

J Pharmacol Exp Ther. 2003 Apr;305(1):9-16. Review.

PMID:
12649347
11.

Cell-type specificity of ectonucleotidase expression and upregulation by 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Wood E, Broekman MJ, Kirley TL, Diani-Moore S, Tickner M, Drosopoulos JH, Islam N, Park JI, Marcus AJ, Rifkind AB.

Arch Biochem Biophys. 2002 Nov 1;407(1):49-62.

PMID:
12392715
12.

Role of extracellular ATP metabolism in regulation of platelet reactivity.

Birk AV, Broekman MJ, Gladek EM, Robertson HD, Drosopoulos JH, Marcus AJ, Szeto HH.

J Lab Clin Med. 2002 Sep;140(3):166-75.

PMID:
12271274
13.

Roles of Asp54 and Asp213 in Ca2+ utilization by soluble human CD39/ecto-nucleotidase.

Drosopoulos JH.

Arch Biochem Biophys. 2002 Oct 1;406(1):85-95.

PMID:
12234494
14.

Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain.

Pinsky DJ, Broekman MJ, Peschon JJ, Stocking KL, Fujita T, Ramasamy R, Connolly ES Jr, Huang J, Kiss S, Zhang Y, Choudhri TF, McTaggart RA, Liao H, Drosopoulos JH, Price VL, Marcus AJ, Maliszewski CR.

J Clin Invest. 2002 Apr;109(8):1031-40.

15.

Role of a novel soluble nucleotide phospho-hydrolase from sheep plasma in inhibition of platelet reactivity: hemostasis, thrombosis, and vascular biology.

Birk AV, Bubman D, Broekman MJ, Robertson HD, Drosopoulos JH, Marcus AJ, Szeto HH.

J Lab Clin Med. 2002 Feb;139(2):116-24.

PMID:
11919550
16.

EctoNucleotidase in cardiac sympathetic nerve endings modulates ATP-mediated feedback of norepinephrine release.

Sesti C, Broekman MJ, Drosopoulos JH, Islam N, Marcus AJ, Levi R.

J Pharmacol Exp Ther. 2002 Feb;300(2):605-11.

PMID:
11805223
17.

Inhibition of platelet recruitment by endothelial cell CD39/ecto-ADPase: significance for occlusive vascular diseases.

Marcus AJ, Broekman MJ, Drosopoulos JH, Pinsky DJ, Islam N, Maliszewsk CR.

Ital Heart J. 2001 Nov;2(11):824-30.

PMID:
11770867
18.

Site-directed mutagenesis of human endothelial cell ecto-ADPase/soluble CD39: requirement of glutamate 174 and serine 218 for enzyme activity and inhibition of platelet recruitment.

Drosopoulos JH, Broekman MJ, Islam N, Maliszewski CR, Gayle RB 3rd, Marcus AJ.

Biochemistry. 2000 Jun 13;39(23):6936-43.

PMID:
10841775
19.

Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39.

Gayle RB 3rd, Maliszewski CR, Gimpel SD, Schoenborn MA, Caspary RG, Richards C, Brasel K, Price V, Drosopoulos JH, Islam N, Alyonycheva TN, Broekman MJ, Marcus AJ.

J Clin Invest. 1998 May 1;101(9):1851-9.

20.

The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39.

Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Alyonycheva TN, Safier LB, Hajjar KA, Posnett DN, Schoenborn MA, Schooley KA, Gayle RB, Maliszewski CR.

J Clin Invest. 1997 Mar 15;99(6):1351-60.

Supplemental Content

Loading ...
Support Center